Freeform Search

Da	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins						
Te	L9 and (verapamil or diltiazem or cinnariz: nifedipine)	ine or					
Dis	Display: 20 Documents in Display Format: - Starting with Number 1						
Ge	nerate: O Hit List . Hit Count O Side by Side O Ima	ge					
Search Clear Interrupt							
	Search History						
DATE:	Tuesday, September 05, 2006 Purge Queries Printab	le Copy Cr	eate Case				
Set Nan	<u>1e Query</u> de	Hit Count S	et Name result set				
•	PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; (result set				
<u>L10</u>	L9 and (verapamil or diltiazem or cinnarizine or nifedipine)) 95	<u>L10</u>				
<u>L9</u>	L8 and ((solution or liquid) same composition)	230	<u>L9</u>				
<u>L8</u>	L7 and propellant	241	<u>L8</u>				
<u>L7</u>	L6 and carrier	990	<u>L7</u>				
<u>L6</u>	L5 and hypertension	1084	<u>L6</u>				
<u>L5</u>	L4 and nasal\$	2102	<u>L5</u>				
<u>L4</u>	(calcium adj channel adj (blocker or antagonist))	8692	<u>L4</u>				
	PGPB,USPT; PLUR=YES; OP=OR						
<u>L3</u>	Karl near Weinrich	5	<u>L3</u>				
<u>L2</u>	Timothy near Maher	20	<u>L2</u>				
<u>L1</u>	(Christopher adj P) near Adams	20	<u>L1</u>				

END OF SEARCH HISTORY





A service of the National Library of Medicine and the National Institutes of Health

My NCBI (Sign In) (Rec

J NCDI			www.p	ubmed.gov				(oigh in)	11.05
All Databases	PubMed	Nucleotide	Protein	Genome	Structure	ОМІМ	PMC	Journals	В
Search PubMed		for calci	um channe	el blocker hyp	ertension ar	id verapar	Go C	ear Sav	ve Si
	Limits		ndex F		.,	Details	[C140	(Fal	
About Entrez	-	Summary 1533 Review	ر: 326 🖈 ع	Show 2	0 Sort t	by 💆	Send to		
Text Version						Perce L			
Entrez PubMed Overview		Items 1 - 20 o	f 326			Page 1		of 17 No	ext
Help FAQ Tutorials	□1:	Triggle DJ.					Related	Articles, L	inks
New/Noteworthy 51 E-Utilities		L-type calciu Curr Pharm Des PMID: 1647213	s. 2006;12(4):443-57. Rev					
PubMed Services Journals Database	□2:	Richard S.					Related	Articles, L	inks.
MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries		Vascular effe Drugs. 2005;65 PMID: 1639805	Suppl 2:1-	10. Review.		ts: new e	vidence.		
Special Queries LinkOut	□ 3:	Fomin VV, Mo	iseev SV.				Related	Articles, L	.inks
My NCBI Related Resources Order Documents NLM Mobile		[Hypertensionshould angiot Should angiot Kardiologiia. 20 PMID: 1635305	tensin cor 005;45(12):	nverting enz 99-102. Revie	yme inhibito w. Russian. N	ors be pre	escribed?		
NLM Catalog NLM Gateway	□ 4:	Karpov luA.					Related	Articles, L	inks
TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central		[Ischemic heacourse and se Kardiologiia. 20 PMID: 1635305	election of 005;45(12):	f therapy] 87-92. Review	. Russian. No			es of	
	□ 5:	Reynolds NA, V	Wagstaff A.	, Keam SJ.			Related	Articles, L	inks
		Trandolapril/ treatment of 6 Drugs. 2005;65 PMID: 1611498	essential l (13):1893-9	nypertensior 914. Review.	1.	view of it	s use in t	the	
	□ 6:	Sica DA.					Related	Articles, L	_inks
		Calcium char pharmacokin J Clin Hyperten PMID: 1585839	etics and is (Greenwi	pharmacody ch). 2005 Apr	namics. 7(4 Suppl 1):	_			
	□ 7:	Sica D.					Related	Articles, L	_inks
		Calcium char Clin Cornerstor	ne. 2004;6(4	l):39-52. Revie	ew.				



Day: Tuesday Date: 9/5/2006 Time: 14:38:17

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Adams	Christopher	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page



PALM INTRANET

Day: Tuesday Date: 9/5/2006 Time: 14:38:17


Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Maher	Timothy	Seerch

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page



Day: Tuesday Date: 9/5/2006 Time: 14:38:17

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name. Additionally, enter the **first few letters** of the Inventor's First name.

Last Name	First Name	
Weinrich	Karl	Search

To go back use Back button on your browser toolbar.

Back to PALM | ASSIGNMENT | OASIS | Home page

(FILE 'HOME' ENTERED AT 16:26:28 ON 05 SEP 2006)

	FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 16:26:48 ON 05 SEP 2006
Ll	13362 S (CALCIUM(W)CHANNEL(W)(BLOCKER OR ANTAGONIST))
L2	31 S L1 (P) (NASAL?)
L3	26 DUPLICATE REMOVE L2 (5 DUPLICATES REMOVED)
L4	26 FOCUS L3 1-

L4ANSWER 2 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN

Nasal administration of calcium channel blockers for treatment of TI

hypertension and other cardiovascular disorders

Pharmaceutical compns. useful for the treatment of cardiovascular AB disorders such as hypertension are described. These compns. are formulated for nasal administration and comprise a therapeutically effective amount of a calcium channel blocker, optionally a pharmaceutically acceptable carrier that is suitable for nasal administration, and one or more optional members selected from excipients and addnl. pharmaceutically active

agents. ACCESSION NUMBER:

2005:961466 CAPLUS

DOCUMENT NUMBER:

143:253914

TITLE:

🕶 ه - سو

Nasal administration of calcium channel blockers for treatment of hypertension and other cardiovascular

disorders

INVENTOR(S):

Adams, Christopher P.; Maher, Timothy; Weinrich, Karl

Ρ.

PATENT ASSIGNEE(S):

USA

SOURCE:

U.S. Pat. Appl. Publ., 19 pp.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
				
US 2005191245	A1	20050901	US 2004-789965	20040227
PRIORITY APPLN. INFO.:			US 2004-789965	20040227

ANSWER 12 OF 26 CAPLUS COPYRIGHT 2006 ACS on STN T.4

TIIntranasal delivery of RS-93522, a dihydropyridine-type calcium-channel antagonist

The nasal route for RS-93522 (I) appears to be as effective as the i.v. AB route. The onset of absorption was rapid and the drug plasma levels after nasal administration were similar to those following i.v. administration. Excellent nasal bioavailability and rapid absorption were observed Therefore, therapeutic treatment with this compound via nasal administration is a viable approach and offers an alternative to oral administration where ineffective and variable absorption is a problem.

ACCESSION NUMBER:

1991:108831 CAPLUS

DOCUMENT NUMBER:

114:108831

TITLE:

Intranasal delivery of RS-93522, a

dihydropyridine-type calcium-channel antagonist Fu, Roger Cherng Chi; Whatley, John L.; Fleitman,

AUTHOR (S):

Jeffrey S.

CORPORATE SOURCE:

Inst. Pharm. Sci., Syntex Res., Palo Alto, CA, 94304,

USA

SOURCE: /

Pharmaceutical Research (1991), 8(1), 134-5

CODEN: PHREEB; ISSN: 0724-8741

DOCUMENT TYPE:

Journal

LANGUAGE:

English